TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ac Immune Sa
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

AC Immune reported promising interim Phase 2 trial results for ACI-7104.056, an active immunotherapy targeting alpha-synuclein, showing potential to slow Parkinson's disease progression with a strong safety profile and 100% antibody responder rate.

Insights
MPLX   positive

Consistent dividend growth since 2012, multiple natural gas pipeline projects, strategic acquisitions, and high dividend yield of 7.4%


ACIU   positive

Positive interim trial results demonstrating potential disease-modifying effects, strong antibody response, and no serious adverse events support promising drug development